In this article, we will list the 5 Best Penny Stocks to Buy for Long Term. Please visit 10 Best Penny Stocks to Buy for Long Term if you would like to see the extended list and the methodology behind it.
5. Savara Inc. (NASDAQ:SVRA)
On May 12, 2026, Savara Inc. (NASDAQ:SVRA) reported Q1 EPS of (15c), versus the consensus estimate of (14c). Chair and CEO Matt Pauls said the company ended the quarter with approximately $203M in cash and expects to have access to as much as $150M in additional non-dilutive funding through debt and royalty financing structures if MOLBREEVI receives approval. Management said this positions the company to support global commercial launch activities. Pauls added that preparations ahead of the November 22 PDUFA date are accelerating, with the company’s Rare Disease Specialist team already focused on increasing awareness of autoimmune PAP and advancing launch readiness for MOLBREEVI, which could become the first approved treatment for the disease.
Last month, Oppenheimer analyst Mazahir Alimohamed assumed coverage of Savara Inc. (NASDAQ:SVRA) with an Outperform rating and raised the firm’s price target to $11 from $9. The firm said the company’s investment story is increasingly centered on regulatory execution and commercialization following the FDA’s Priority Review for the BLA submission of molgramostim, an inhaled GM-CSF therapy. Oppenheimer added that data from the Phase 3 IMPALA-2 study in autoimmune PAP support a high-probability approval outlook, noting that prior FDA feedback was primarily related to chemistry, manufacturing, and controls.
Savara Inc. (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on therapies for rare respiratory diseases.
4. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
On May 11, 2026, Citi raised the firm’s price target on Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) to $3.10 from $2.30 and maintained a Buy rating following the company’s Q1 2026 earnings report.
On May 7, 2026, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported Q1 EPS of 0c, versus the consensus estimate of (4c). Revenue came in at $21.1M, well above the consensus estimate of $9.78M, driven primarily by a $20M development milestone payment from Novo Nordisk and $1.1M in net sales from Inpefa. CEO Mike Exton said the company has remained focused on advancing both its late-stage and early-stage cardiometabolic pipeline and believes it is now positioned to deliver several important regulatory and development milestones.
Earlier in May, Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) also announced a new loan agreement with Hercules Capital that provides up to $100M in borrowing capacity. The financing is intended to improve the company’s financial flexibility and support upcoming regulatory and commercial milestones without shareholder dilution. Under the agreement, Lexicon received an initial $55M tranche at closing, which was used to repay its prior loan facility with Oxford Finance. Additional tranches totaling $45M may become available based on certain clinical, regulatory, and financial milestones, along with lender approval requirements.
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is a biopharmaceutical company focused on developing and commercializing therapies for human disease.
3. HIVE Digital Technologies Ltd. (NASDAQ:HIVE)
On May 19, 2026, Cantor Fitzgerald analyst Brett Knoblauch raised the firm’s price target on HIVE Digital Technologies Ltd. (NASDAQ:HIVE) to $4.60 from $3 and maintained an Overweight rating on the shares. The firm cited HIVE’s newly announced AI data center expansion in the Greater Toronto Area, which targets approximately 320 megawatts of utility capacity and represents a significant move deeper into AI infrastructure. Cantor estimates the project could require roughly $3.5B in total investment and potentially come online in the second half of 2027. The firm added that the development meaningfully improves HIVE’s long-term compute supply visibility and could strengthen its position in securing large-scale cloud tenancy agreements that may help support financing for the buildout.
A day earlier, HIVE Digital Technologies Ltd. (NASDAQ:HIVE), through its wholly owned subsidiary BUZZ High Performance Computing, announced plans to advance a large-scale AI infrastructure project in Ontario. The planned facility in the Greater Toronto Area is expected to have approximately 320 MW of utility capacity and is being positioned as one of Canada’s largest AI gigafactories. Management said the site is intended to support vertically integrated AI supercomputing infrastructure and could host more than 100,000 GPUs once fully built out.
HIVE Digital Technologies Ltd. (NASDAQ:HIVE) operates green-energy-powered data centers and digital infrastructure operations in Bermuda and Paraguay.
2. CytomX Therapeutics, Inc. (NASDAQ:CTMX)
On May 19, 2026, Wolfe Research initiated coverage of CytomX Therapeutics, Inc. (NASDAQ:CTMX) with an Outperform rating and a $6 price target. The firm said CytomX currently has the only de-risked epithelial cell adhesion molecule, or EpCAM, antibody-drug conjugate in clinical development. While toxicity remains a key area of focus, Wolfe believes the company can manage safety concerns and maintain acceptable Grade 3 adverse event rates. The firm also characterized the recent weakness in the stock as a potential buying opportunity.
Meanwhile, H.C. Wainwright lowered the firm’s price target on CytomX Therapeutics, Inc. (NASDAQ:CTMX) to $11 from $17 and maintained a Buy rating on the shares. The revised target primarily reflected dilution tied to the company’s recent financing activities.
On May 7, 2026, CytomX Therapeutics, Inc. (NASDAQ:CTMX) reported Q1 EPS of (10c), versus the consensus estimate of (11c). Revenue came in at $10.26M, versus the consensus estimate of $4.68M. Chairman and CEO Sean McCarthy said the company has continued to build momentum in 2026 and remains focused on advancing Varseta-M, its EpCAM ADC candidate, into a registrational study for late-line colorectal cancer. Management also said the company is continuing to invest in exploring broader applications for Varseta-M across earlier-line colorectal cancer settings and additional tumor types.
CytomX Therapeutics, Inc. (NASDAQ:CTMX) is an oncology-focused biopharmaceutical company developing conditionally activated biologics designed to target the tumor microenvironment.
1. Precigen, Inc. (NASDAQ:PGEN)
On May 14, 2026, H.C. Wainwright raised the firm’s price target on Precigen, Inc. (NASDAQ:PGEN) to $11 from $10 and kept a Buy rating on the shares following the company’s Q1 report. The firm said PAPZIMEOS sales comfortably exceeded guidance.
Citizens also raised the firm’s price target on Precigen, Inc. (NASDAQ:PGEN) to $11 from $9 and keeps an Outperform rating on the shares. The firm said it was impressed by the strength of the PAPZIMEOS launch, citing the product’s clinical profile, commercial preparation efforts, and launch execution.
On May 13, 2026, Precigen, Inc. (NASDAQ:PGEN) reported Q1 EPS of (2c), compared to (18c) in the prior-year period. Revenue totaled $23.25M, versus the consensus estimate of $20.8M. CEO Helen Sabzevari said the company was encouraged by the pace of PAPZIMEOS revenue growth as it works to expand commercialization across the U.S. and pursue additional opportunities in international and pediatric markets. Sabzevari also highlighted continued development of PRGN-2009 in HPV-associated cancers as part of the company’s AdenoVerse platform pipeline. CFO Harry Thomasian Jr. said Precigen recognized $21.6M in net PAPZIMEOS revenue during the product’s first full commercial quarter and noted that Q2 has continued to show strong revenue momentum. As of March 31, 2026, the company had $56.7M in cash, cash equivalents, and investments, excluding approximately $25.7M in PAPZIMEOS-related accounts receivable that had not yet been collected. Management said it continues to expect current cash resources and anticipated PAPZIMEOS sales to fund operations through cash flow break-even by the end of 2026.
Precigen, Inc. (NASDAQ:PGEN) is a clinical-stage biopharmaceutical company developing gene and cell therapies focused on immuno-oncology, autoimmune disorders, and infectious diseases.
While we acknowledge the potential of PGEN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PGEN and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 AI Stocks with Potential to Rise 1000 Percent and 9 Best American Semiconductor Stocks to Buy According to Analysts
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.
Hedge Fund Resource Center